Amylyx Pharmaceuticals, Inc. Common Stock AMLX
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Amylyx Pharmaceuticals, Inc. Common Stock represents ownership in a clinical-stage biopharmaceutical company dedicated to developing investigational therapies for neurodegenerative diseases and endocrine conditions. The company focuses on advancing its pipeline, including avexitide, a first-in-class GLP-1 receptor anta…
SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited States
Employees136
TickerAMLX
Statistics
Market Cap$1.70B
Revenue (TTM)$0
Net Income-$144.7M
Net Margin—
EPS$-1.53
P/E2.54
P/S—
P/B5.65
EV/EBITDA-8.01
ROE-63.3%
Dividend Yield—
Price$15.33
Data: Twelve Data · Revenue = mcap / P/S